Clinical trial
ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease…
NCT00231946 · Voyager Pharmaceutical Corporation, Industry · Completed
Key facts
| NCT number | NCT00231946 |
|---|---|
| Title | ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) |
| Official title | A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease |
| Lead sponsor | Voyager Pharmaceutical Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | VP4896 |
| Enrollment | 555 |
| Start date | Sep 1, 2005 |
| First posted | Oct 4, 2005 |
| Last update posted | Sep 20, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: